(Q83202996)

English

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years

scientific article published on 01 June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

breast carcinoma

1 reference

based on heuristic

inferred from title

Richard E Champlin

11

object named as

Richard E Champlin

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

S. Eva Singletary

8

object named as

Sonja E Singletary

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

object named as

Aman U Buzdar

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Emer O Hanrahan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kristine Broglio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Deborah Frye

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Richard L Theriault

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Vicente Valero

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Daniel J Booser

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Eric A Strom

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

James L Gajewski

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Gabriel N Hortobagyi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

106

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2327-2336

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Dose-response in the treatment of breast cancer: a critical review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

21 January 2018

Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year results of FAC adjuvant chemotherapy trial in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy for breast cancer: the French PEGASE experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21906

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21906

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16639731%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83202996&oldid=2121328845"